
-
Lantern Pharma NasdaqCM:LTRN Lantern Pharma Inc. focuses on the discovery and development of oncology drug. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, as well as glioblastoma and other central nervous system (CNS) cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma. The company also develops STAR-001, which is in preclinical development for the treatment of glioblastoma, brain metastases, atypical teratoid rhabdoid tumors, and several rare pediatric CNS cancers. In addition, it provides ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. The company has a strategic AI-driven collaboration with Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase inhibitor drug candidate XCE853 in novel and targeted cancer indications; a collaboration agreement with TTC Oncology, which focuses on the drug development of TTC-352 to treat patients with metastatic ER+ breast cancer; and a collaboration agreement with Actuate Therapeutics, Inc. that focuses on the development of compounds for use in the treatment of cancer and inflammatory diseases. The company was incorporated in 2013 and is headquartered in Dallas, Texas.
Location: 1920 McKinney Avenue, Dallas, TX, 75201, United States | Website: https://www.lanternpharma.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
17.86M
Cash
24.01M
Avg Qtr Burn
-4.453M
Short % of Float
3.17%
Insider Ownership
14.72%
Institutional Own.
22.74%
Qtr Updated
12/31/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
LP-300 Details Non-small cell lung carcinoma, Cancer | Phase 2 Data readout | |
LP-100 (Irofulven) Details Cancer, Castration-resistant prostate cancer | Phase 2 Update | |
LP-184 Details Triple Negative Breast Cancer | Phase 1/2 Data readout | |
LP-184 Details Non-small cell lung carcinoma | Phase 1/2 Initiation | |
LP-284 Details Cancer, Non-Hodgkin lymphoma, Mantle cell lymphoma, High-grade Glioma
| Phase 1 Data readout | |
LP-184 Details Brain tumors (Pediatrics) | Phase 1 Initiation | |
LP-184 Details Cancer, Solid tumor/s, Central nervous system illness | Phase 1a Data readout |